首页> 中文期刊>中国药业 >2008年至2012年某三甲医院门诊消化系统药物利用分析

2008年至2012年某三甲医院门诊消化系统药物利用分析

     

摘要

Objective To understand the utilization status quo of digestive system drugs to provide reference for clinical rational drug use. Methods The related data of digestive system drug use in a grade 3 A hospital during 2008 - 2012 were extracted for conducting the statistical analysis on drug sales amount,DDDs and average daily cost(DDC). Results The use quantity and consumption sum of digestive system drugs showed an increasing trend year by year;the top three in the consumption sum were the gastric acid secretion inhibitors,auxiliary drugs of hepatobiliary disease,gastric mucosal protective drugs;the drugs with high DDDs were gastric acid secretion inhibitors,gastrointestinal prokinetic drugs;the top drug in sales amounts in recent 5 years was rabeprazole sodium;the serial number ra-tio in top 10 drugs in DDDs ranking basically approached to 1,the DDC value was lower. Conclusion The use amount of digestive system drugs is generally increased,moreover the drug ranking changes little,DDC is lower,the drug use in the outpatient department is relatively rational.%目的:了解消化系统药物的利用现状和趋势,为临床合理用药提供参考。方法调取2008年至2012年某三甲医院消化系统药物使用的相关数据,对销售金额、用药频度(DDDs)、日均费用(DDC)等数据进行统计和分析。结果消化系统药物的使用数量及销售金额逐年上升;销售金额排序前3位分别是胃酸分泌抑制药、肝胆疾病辅助用药、胃黏膜保护药;DDDs 较高的为胃酸分泌抑制药、促胃肠动力药;销售金额近5年排首位的是雷贝拉唑钠;DDDs 排序前10位药物的序号比基本趋近于1,DDC 值较低。结论消化系统药物用量在普遍增加,且药品排序变化不大,日均用药费用较低,该院门诊用药较合理。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号